ArticleEmergency medicine journal : EMJ2022
COVID-19 rapid diagnostics: practice review.
Article in Emergency medicine journal : EMJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- FebriDx for rapid screening of patients with suspected COVID-19 upon hospital admission: systematic literature review and meta-analysis.The Journal of hospital infection · 2022Pooled it
- An umbrella protocol for the clinical evaluation of diagnostics in infectious disease.Bulletin of the World Health Organization · 2026Article
- Establishment of a Padlock Probe-Based Fluorescence Quantitative PCR Method for the Detection of the SARS-CoV-2 Omicron S371L Mutation.Journal of fluorescence · 2026Article
- Feasibility of snapshot testing using wearable sensors to detect cardiorespiratory illness (COVID infection in India).NPJ digital medicine · 2024Article
- Prevalence, under-reporting, and epidemiological surveillance of COVID-19 in the Araguaína City of Brazil.PloS one · 2024Article
- Detection of live SARS-CoV-2 virus and its variants by specially designed SERS-active substrates and spectroscopic analyses.Analytica chimica acta · 2023Article
- Emerging Landscape of SARS-CoV-2 Variants and Detection Technologies.Molecular diagnosis & therapy · 2023Review
- A capacitive laser-induced graphene based aptasensor for SARS-CoV-2 detection in human saliva.PloS one · 2023Article
- Stakeholder perspectives of piloting pre-hospital COVID-19 lateral flow testing and direct admissions pathway: exploring why well-received ideas have low uptake.British paramedic journal · 2022Article
- Mini-evaluation of the Lyra SARS-CoV-2 assay to detect Omicron BA.1 and BA.2 in nasopharyngeal swabs.Journal of clinical virology plus · 2022Article
- Article
- Diagnostic accuracy of the Abbott ID NOW SARS-CoV-2 rapid test for the triage of acute medical admissions.The Journal of hospital infection · 2022Article
- COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review.International journal of immunopathology and pharmacologyReview
Corrections and comments
- Commented on by
- Commented on byReply to Mouliou2022
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-care tests for SARS-CoV-2 could enable rapid rule-in and/or rule-out of COVID-19, allowing rapid and accurate patient cohorting and potentially reducing the risk of nosocomial transmission. As COVID-19 begins to circulate with other more common respiratory viruses, there is a need for rapid diagnostics to help clinicians test for multiple potential causative organisms simultaneously.However, the different technologies available have strengths and weaknesses that must be understood to ensure that they are used to the benefit of the patient and healthcare system. Device performance is related to the deployed context, and the diagnostic characteristics may be affected by user experience.This practice review is written by members of the UK's COVID-19 National Diagnostic Research and Evaluation programme. We discuss relative merits and test characteristics of various commercially available technologies. We do not advocate for any given test, and our coverage of commercially supplied tests is not intended to be exhaustive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.